21 results about "Phospholipase" patented technology

To provide therapies for subjects suffering from NAFLD.SOLUTION: A double stranded ribonucleic acid (RNAi) agent for inhibiting expression of Patatin-Like Phospholipase Domain Containing 3 is used which comprises a sense strand and an antisense strand. The sense strand comprises at least 15 contiguous nucleotides differing by 3 or less nucleotides from a specific nucleotide sequence. The antisense strand comprises at least 15 contiguous nucleotides differing by 3 or less nucleotides from another specific nucleotide sequence.SELECTED DRAWING: Figure 1

The application provides a lipoprotein phospholipase A2 determination kit for latex immunoturbidimetry, which contains reagent R1 and reagent R2; the reagent R1 comprises the following components: buffer, inorganic salt, anti-interference additive, surfactant and Proclin 300; the reagent R2 comprises the following components: buffer, lipoprotein phospholipase A2 antibody coated latex microspheres, stabilizer, surfactant and Proclin 300. The kit is a liquid kit with strong stability, high accuracy, wide linear range and strong anti-HOOK capability.

This invention discloses a phospholipase D and its application in the preparation of ω-3 PUFAs-PA, belonging to the field of functional enzyme technology. The amino acid sequence of the phospholipase D is shown in SEQ ID NO. 9. The application of phospholipase D in the preparation of ω-3 PUFAs-PA is also disclosed. This invention also discloses a recombinant engineered bacterium expressing OUC-nPLD. The phospholipase D of this invention—OUC-nPLD—is a recombinant enzyme obtained by functional domain recombination based on the Non-HKD phospholipase D of *Streptomyces aquamarine*, and its PLD hydrolytic activity is 221.73 U / mg. This invention constructs a recombinant engineered bacterium expressing OUC-nPLD. The OUC-nPLD of this invention can be used for the efficient preparation of ω-3 PUFAs-PA, which is of great significance for the large-scale production of ω-3 PUFAs-PA.

The invention relates to compounds of Formula (I), and pharmaceutically acceptable salts and isomers of such compounds, which bind to patatin-like phospholipase domain-containing protein 3 (PNPLA3) mutation PNPLA3I148M, (I) pharmaceutical compositions comprising a compound of Formula (I), or pharmaceutically acceptable salts thereof, and their use in methods for the treatment of diseases associated with PNPLA3I148M.

This invention provides a mutant phospholipase D for the efficient synthesis of phosphatidylserine, its products, and applications. The mutant is based on phospholipase D with the amino acid sequence shown in SEQ ID NO.1, obtained by mutating one or more of five sites at positions 87, 136, 189, 379, and 458 of this amino acid sequence. The amino acid mutation types at these sites include: L87E, M136G, I189R, E379L, and A458Y. This invention provides both a mutant phospholipase D and its applications. This mutant phospholipase D exhibits improved thermostability and catalytic activity, enabling the catalytic preparation of phosphatidylserine series products. The phosphatidylserine series products prepared using this enzyme can effectively alleviate metabolic syndrome induced by antipsychotic drugs.

The application relates to a preparation method of immobilized phospholipase D and a preparation method of phosphatidylserine thereof, and belongs to the technical field of biotechnology.The preparation method of the immobilized phospholipase D comprises the following steps: (1) mixing mesoporous molecular sieve SBA-15 and a sodium acetate buffer solution to obtain a mixed solution; (2) mixing the mixed solution with an enzyme solution, oscillating, centrifuging, taking the precipitate, cleaning and freeze-drying to obtain the immobilized phospholipase D.The application improves the catalytic performance and stability of PLD by fixing PLD through the immobilization technology, realizes the reusability of PLD, and provides technical support for the industrialized production of the immobilized enzyme of PS.The preparation of phosphatidylserine by the immobilized PLD is optimized, and the optimal process condition of the preparation of PS by the immobilized PLD is obtained.The application further discloses a potential molecular mechanism of PS in treating AD, and provides a theoretical basis for the further clinical application of PS.

The application discloses a panax notoginseng phospholipase gene PnPLA1-21 and application thereof. The nucleotide sequence of the PnPLA1-21 gene is shown as SEQ ID NO:1, and the protein encoded by the PnPLA1-21 gene is shown as SEQ ID NO:2. The application clones the gene, constructs an RNAi carrier pHellsgate 2-PnPLA1-21 by using a Gateway technology, transforms the agrobacterium after the PnPLA1-21 gene in panax notoginseng leaves is instantaneously silenced, inoculates fusarium solani, and carries out resistance analysis. The results show that the disease spot area of the panax notoginseng leaves is significantly expanded after the RNAi silencing, is about 2 times of that of a control group, and the expression level of the PnPLA1-21 is positively correlated with the disease resistance. The application proves for the first time that the PnPLA1-21 positively regulates the resistance of panax notoginseng to the root rot pathogenic bacteria, and can be used for cultivating transgenic panax notoginseng plants resistant to the root rot, and provides new gene resources and technical support for panax notoginseng disease resistance breeding.

This invention belongs to the field of molecular biology technology, specifically disclosing the application of the phospholipase PLA2G7 gene in the preparation of a formulation that enhances the anti-Salmonella activity of avian macrophages. The avian species is chicken. The CDS sequence of the phospholipase PLA2G7 gene is shown in SEQ ID NO:1. By increasing the expression level or activity of the phospholipase PLA2G7 gene in chicken macrophages, the invention promotes the expression of pro-inflammatory factors in chicken macrophages and enhances their phagocytic and bactericidal ability against Salmonella. Compared with existing technologies, this invention demonstrates that increasing the expression level or activity of the phospholipase PLA2G7 gene in chicken macrophages can promote the expression of pro-inflammatory factors in chicken macrophages and enhance their phagocytic and bactericidal ability against Salmonella.

The application discloses corn phosphatidyl phospholipase C4, a coding gene thereof and application of the corn phosphatidyl phospholipase C4 in enhancing disease resistance. The corn phosphatidyl phospholipase C4 can endow transgenic rice with wide resistance without affecting the yield of the rice. The amino acid sequence of the corn phosphatidyl phospholipase C4 is SEQ ID No.2. The sequence of the coding gene is SEQ ID No.1. Research shows that the corn phosphatidyl phospholipase C4 gene is located in the cell membrane, overexpression of the corn phosphatidyl phospholipase C4 gene in rice can improve the resistance of the rice to rice blast caused by Magnaporthe oryzae and rice bacterial leaf blight caused by Xanthomonas oryzae, and meanwhile, the agronomic characters of the rice are evaluated, and it is found that the gene does not affect the ear length, grain length, 1000-grain weight and yield per plant of the rice.

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts and isomers of such compounds that bind to patatin-like phospholipase domain-containing protein 3 (PNPLA3) mutant PNPLA3 I148M, (I) pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and their use in methods for treating PNPLA3 I148M-associated diseases.(I)

The invention relates to compounds of Formula (I), and pharmaceutically acceptable salts and isomers of said compounds, which bind to the patatin-like phospholipidase domain-containing protein 3 (PNPLA3) mutation PNPLA3I148M, (I) pharmaceutical compositions comprising a compound of Formula (I), or pharmaceutically acceptable salts thereof, and their use in methods for the treatment of diseases associated with PNPLA3I148M.

To provide a new method for improving the taste of food products. [Solution] To provide a food flavor enhancer containing phospholipase D and γ-glutamyl peptide or a salt thereof.

The present invention relates to a method of preparing a protein composition, comprising enzymatic modification of milk lecithin using phospholipase. This protein composition is then included in nutritional products to increase emulsion quality and heat stability of the final nutritional products.

This invention discloses a method for recovering L-serine based on the enzymatic synthesis reaction solution of phosphatidylserine, comprising the following steps: phosphatidylcholine and L-serine undergo an enzymatic reaction under the catalysis of phospholipase, resulting in a mixed aqueous solution containing L-serine and choline; porous media and alcohol are added to the obtained mixed aqueous solution of L-serine and choline, causing crystals to precipitate, resulting in a solid mixture of L-serine and porous media; the solid mixture of L-serine and porous media is obtained through solid-liquid separation; the obtained solid mixture of L-serine and porous media is dissolved in water, and after solid-liquid separation, an L-serine solution is obtained. This invention adds porous media before crystallization, causing capillary phase separation in the L-serine aqueous solution. This capillary phase separation results in a lower saturation concentration required for L-serine crystallization and a smaller amount of ethanol consumed, thus reducing the production cost of phosphatidylserine.

A processing method for long-shelf-life whole egg liquid includes the following steps: S1, raw material pretreatment; S2, primary enzymatic hydrolysis of whole egg liquid; S3, secondary enzymatic hydrolysis of whole egg liquid; S4, degassing and cooling; S5, filling; and S6, ultra-high pressure sterilization. This invention employs a synergistic process of "stepwise enzymatic hydrolysis + vacuum degassing + ultra-high pressure sterilization." Phospholipase hydrolysis of the whole egg liquid improves its stability and generates antibacterial components. Subsequent bromelain-transglutaminase complex enzymatic hydrolysis produces antimicrobial peptides through proteolysis while simultaneously preventing excessive protein degradation and inhibiting microbial growth through transglutaminase. Combined with vacuum degassing to reduce oxidizing agents and the highly efficient antibacterial effect of ultra-high pressure sterilization, the finished whole egg liquid can achieve a shelf life of over 37 days under 4°C refrigeration conditions, far exceeding the traditional 15-21 days for whole egg liquid, thus solving the spoilage problem during storage and distribution.

This invention discloses a *Serratia marcescens* strain for producing levonorgestrel and its applications, belonging to the field of bioengineering technology. This invention provides a method for producing levonorgestrel using the halophilic archaea MVA pathway in *Serratia marcescens*. The production and yield of levonorgestrel are increased through pathway construction, enhanced soluble expression of levonorgestrel synthase, and knockout of endogenous phospholipase. The engineered *Serratia marcescens* strain for producing levonorgestrel constructed in this invention achieves a yield of 73.4 g·L⁻¹ of levonorgestrel in a 30 L fermenter. ‑1 .

The present invention relates to a polynucleotide encoding a mutated patatin phospholipase protein, which mutated protein leads to an improved haploid induction rate. The invention further relates to the mutant patatin phospholipase protein and to methods and compositions for improved plant breeding using haploid induction. Sorghum plants which are capable of haploid induction with improved induction performance are described.

We provide treatment for individuals suffering from non-alcoholic fatty liver disease (NAFLD). [Solution] A double-stranded ribonucleic acid (dsRNA) for inhibiting intracellular PNPLA3 expression is provided, comprising a sense strand and an antisense strand forming a double-stranded region, wherein the antisense strand comprises a complementary region to mRNA encoding patatin-like phospholipase domain 3 (PNPLA3), and the complementary region comprises at least 15 consecutive nucleotides that differ by 3 nucleotides or less from any one of the antisense nucleotide sequences in any one of a specific set of sequences.

This invention belongs to the field of edible oil cold pressing technology, specifically relating to a structure and method for cold pressing flaxseed and sunflower oil mixture. The method includes the following steps: S1, pure flaxseed and pure sunflower seeds are blended according to a preset mass ratio; S2, the pure flaxseed and pure sunflower seeds are respectively sent to independent conditioning units for differentiated conditioning and low-temperature targeted enzyme passivation treatment, and then respectively subjected to band-matched short-time infrared pre-cooking treatment to obtain plasticity-matched mixed conditioning kernel material; S3, a five-stage variable pressure pressing process of pre-pressure degassing-low-pressure primary pressing-medium-pressure buffering-high-pressure final pressing-pressure release and pulp discharge is adopted to collect the crude oil from the low-pressure primary pressing stage and the crude oil from the high-pressure final pressing stage, and combine them to obtain mixed cold-pressed crude oil; S4, the mixed cold-pressed crude oil is subjected to phospholipase-assisted low-temperature in-situ targeted degumming treatment under high-purity inert gas protection throughout the process, and then sent to a fully enclosed gradient ceramic membrane filtration system for graded fine filtration; finally, the finished flaxseed and sunflower mixed cold-pressed oil is obtained.

FIELD: surgery.SUBSTANCE: used to predict the effectiveness of treatment of acute pancreatitis in the early stages. On the 1st, 4th, 7th and 11th days after hospitalization, venous blood sampling is performed from patients, the level of C-reactive protein, the activity of phospholipase A2 and alpha-amylase in the blood is assessed, and an ultrasound of the abdominal cavity is performed to identify fluid formation in the abdominal cavity. In patients with acute pancreatitis, the probability of developing complications IRO is calculated using the stated formula. With the IRO value less than 3.1 predicts high treatment effectiveness, indicating the absence of the likelihood of complications. With an IRO value from 3.2 to 4.5, average treatment effectiveness is predicted, indicating possible disease progression and development of complications and the need for constant monitoring. If the IRO value is more than 4.5, the treatment is predicted to be ineffective, indicating a high probability of complications and requiring urgent puncture interventions at the site and adjustments to treatment regimens.EFFECT: method provides the possibility of increasing the accuracy of assessing the treatment of acute pancreatitis in the early stages, predicting the course of acute pancreatitis and optimizing treatment by preventing the risk of fluid formations, due to the assessment of the state of the components of the homeostasis system: pancreatogenic, immunoinflammatory, membrane-destabilizing, and visual diagnostics of the abdominal cavity to identify fluid formations in it.1 cl, 4 tbl, 3 ex